uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, presented preclinical ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA Management Comments

uniQure (QURE) Highlights New Data from Phase I/II Clinical trial of AMT-060 Showing Successful Liver Transduction with AAV5 Vector May 21, 2018 7:06 AM uniQure Presents Preclinical Data Demonstrating Advances in the Distribution of Gene TherapyMay 18, 2018 7:00 AM Wells Fargo Starts uniQure BV (QURE) at OutperformMay 16, 2018 5:25 AM